Humanitas Global Health Announces Launch and LSU DeepDrug License Agreement at AAPS PharmSci 360
Humanitas Global Health debuts at the American Association of Pharmaceutical Scientists’ 2026 PharmSci 360 congress Humanitas Global Health, a mission-driven initiative applying explainable, traceable artificial intelligence and breakthrough science to reduce preventable suffering and increase access to better care worldwide, has announced its launch and an agreement licensing DeepDrug technologies from Louisiana State University for commercialization. The company marks its launch during the American Association of Pharmaceutical Scientists’ 2026 PharmSci 360 conference in New Orleans. The license agreement provides a foundation for Humanitas to commercialize DeepDrug technology for pharmaceutical development and prescription safety. Humanitas' drug discovery approach uses AI and ethical intelligence to identify and prioritize candidates, linking predictions to physicochemical properties and pharmacologic and toxicologic mechanisms. The firm also introduces Ethical Intelligence (EI), an approach to artificial intelligence that embeds ethical principles and respect for human dignity into system design.
게시됨 : 어제 ~에 의해 Humanitas Global Health Inc. - (GLOBE NEWSWIRE) ~에 Health Tech Science
NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Humanitas Global Health, a mission-driven initiative applying explainable, traceable artificial intelligence and breakthrough science to reduce preventab... [5850 symbols]
주제: Louisiana State University, Academia
